2-(3-甲氧基苄基)哌啶 | 108958-36-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 2-(3-甲氧基苄基)哌啶
• 英文名称: 2-(3-methoxybenzyl)piperidine
• 英文别名: 2-(3-Methoxy-benzyl)-piperidine；2-[(3-methoxyphenyl)methyl]piperidine
• CAS: 108958-36-7
• 化学式: C₁₃H₁₉NO
• 分子量: 205.3
• InChiKey: CHHYHKDNUNRTRY-UHFFFAOYSA-N

物化性质

• 沸点：
  311℃
• 密度：
  1.002
• 闪点：
  128℃

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  2-(3-甲氧基苄基)哌啶 在 lithium aluminium tetrahydride 作用下， 以 吡啶 、 乙醚 、 氯仿 为溶剂， 反应 48.0h， 生成 2-[(3-methoxyphenyl)methyl]-1-methylpiperidine
  参考文献：
  名称：

  Cardellini; Claudi; Perlini, Farmaco, Edizione Scientifica, 1987, vol. 42, # 4, p. 307 - 317

  摘要：

  DOI：
• 作为产物：
  描述：

  3-甲氧基苯乙腈 在 platinum(IV) oxide 氢氧化钾 、 磷酸 、 氢气 、 sodium hydride 作用下， 以 溶剂黄146 、 甲苯 为溶剂， 20.0~120.0 ℃ 、206.84 kPa 条件下， 反应 16.0h， 生成 2-(3-甲氧基苄基)哌啶
  参考文献：
  名称：

  Cardellini; Claudi; Perlini, Farmaco, Edizione Scientifica, 1987, vol. 42, # 4, p. 307 - 317

  摘要：

  DOI：

文献信息

• [EN] 1,2,4 TRIAZOLO [4, 3 -A] [1,5] BENZODIAZEPIN-5 (6H) -ONES AS AGONISTS OF THE CHOLECYSTOKININ-1 RECEPTOR (CCK-IR)<br/>[FR] 1,2,4 TRIAZOLO[4,3-A][1,5] BENZODIAZÉPIN-5(6H)-ONES UTILISÉES COMME AGONISTES DU RÉCEPTEUR DE LA CHOLÉCYSTOKININE-1 (CCK-1R)
  申请人：PFIZER

  公开号：WO2010067233A1

  公开（公告）日：2010-06-17

  This invention relates to CCK-1 R agonists of Formula (I) wherein R1-R5 and X are as defined in the specificiation, as well as pharmaceutical compositions containing the compounds and methods of use of the compounds and compositions. The compounds are useful in treating obesity, type 2 diabetes and associated diseases.

  这项发明涉及到式（I）中的CCK-1 R激动剂，其中R1-R5和X如规范中所定义，以及含有这些化合物的药物组合物和这些化合物和组合物的使用方法。这些化合物在治疗肥胖症、2型糖尿病及相关疾病方面是有用的。
• [EN] ANILINOPYRIMIDINES AS HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS<br/>[FR] ANILINOPYRIMIDINES EN TANT QU'INHIBITEURS DE KINASE 1 PROGÉNITRICES HÉMATOPOÏÉTIQUES (HPK1)
  申请人：ARIAD PHARMA INC

  公开号：WO2018102366A1

  公开（公告）日：2018-06-07

  The invention relates to HPK1 inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: where A, R1, R2, R3, R4, R5, R6, R16, R17, X1, X2, X3, X4, m, and n are described herein.

  这项发明涉及用于治疗癌症和其他丝氨酸-苏氨酸激酶介导的疾病的HPK1抑制剂，其化学式为：其中A、R1、R2、R3、R4、R5、R6、R16、R17、X1、X2、X3、X4、m和n如本文所述。
• INHIBITORS OF ION CHANNELS
  申请人：Marron Brian Edward

  公开号：US20090143358A1

  公开（公告）日：2009-06-04

  Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides substituted aryl sulfonamides, compositions comprising these compounds, as well as methods of using these compounds or compositions in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a voltage-gated sodium channel.

  本发明提供了化合物、组合物和方法，通过抑制电压门控钠通道中的钠离子流来治疗疾病。更具体地，本发明提供了取代芳基磺酰胺、包含这些化合物的组合物，以及使用这些化合物或组合物治疗中枢或外周神经系统疾病，特别是疼痛和慢性疼痛的方法，通过阻止与所示疾病的发生或复发有关的钠通道。本发明的化合物、组合物和方法特别适用于通过抑制电压门控钠通道中的离子流来治疗神经病理性或炎症性疼痛。
• Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors
  申请人：Ariad Pharmaceuticals, Inc.

  公开号：US11180482B2

  公开（公告）日：2021-11-23

  The invention relates to HPK1 inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: where A, R1, R2, R3, R4, R5, R6, R16, R17, X1, X2, X3, X4, m, and n are described herein.

  本发明涉及可用于治疗癌症和其他丝氨酸-苏氨酸激酶介导的疾病的 HPK1 抑制剂，其式如下： 其中 A、R1、R2、R3、R4、R5、R6、R16、R17、X1、X2、X3、X4、m 和 n 如本文所述。
• Triazole Ureas Act as Diacylglycerol Lipase Inhibitors and Prevent Fasting-Induced Refeeding
  作者：Hui Deng、Sander Kooijman、Adrianus M. C. H. van den Nieuwendijk、Daisuke Ogasawara、Tom van der Wel、Floris van Dalen、Marc P. Baggelaar、Freek J. Janssen、Richard J. B. H. N. van den Berg、Hans den Dulk、Benjamin F. Cravatt、Herman S. Overkleeft、Patrick C. N. Rensen、Mario van der Stelt

  DOI：10.1021/acs.jmedchem.6b01482

  日期：2017.1.12

  Triazole ureas constitute a versatile class of irreversible inhibitors that target serine hydrolases in both cells and animal models. We have previously reported that triazole ureas can act as selective and CNS-active inhibitors for diacylglycerol lipases (DAGLs), enzymes responsible for the biosynthesis of 2-arachidonoylglycerol (2 -AG) that activates cannabinoid CB1 receptor. Here, we report the enantio- and diastereoselective synthesis and structure-activity relationship studies. We found that 2,4 -substituted triazole ureas with a biphenylmethanol group provided the most optimal scaffold. Introduction of a chiral ether substituent on the 5 -position of the piperidine ring provided ultrapotent inhibitor 38 (DH376) with picomolar activity. Compound 38 temporarily reduces fasting -induced refeeding of mice, thereby emulating the effect of cannabinoid' CB1-receptor inverse agonists. This was mirrored by 39 (DO34) but also by the negative control compound 40 (DO53) (which does not inhibit DAGL), which indicates the triazole ureas may affect the energy balance in mice through multiple molecular targets.